Method for testing possibility of having contracted prostate cancer
Patent Information
- Application Number
- JP2022574004
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-24
- Filing Date
- 2021-12-24
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2041-12-24
AI Technical Summary
Current prostate cancer testing methods, such as PSA blood tests and invasive needle biopsies, face challenges with false positives, invasiveness, and risks of infection, while existing animal-based detection techniques are not widely adopted.
A method using gas chromatography mass spectrometry to measure specific biomarkers like Dymethyl glutarate, 2,6-Xylidine, 2-Hydroxy-2-methylpropiophenone, and 3,5,5-Trimethyl-2-cyclohexenone in body fluid samples to determine the presence of prostate cancer, with reference values to assess the likelihood of the disease.
This approach provides a non-invasive, accurate, and reliable method for detecting prostate cancer, reducing false positives and the risk of misdiagnosis, and can be used for early detection and monitoring treatment effects.
Abstract
Description
How to test for possible prostate cancer
[0001] The present disclosure relates to a method for testing the possibility of developing prostate cancer.
[0002] Prostate cancer has a high incidence rate among men, with over 100,000 new cases diagnosed annually. Furthermore, with the Westernization of dietary habits and an aging population, the incidence rate and number of men diagnosed with prostate cancer are expected to continue to increase. As with other cancers, early detection and treatment are crucial.
[0003] Screening for prostate cancer is performed using blood PSA (Prostate Specific Antigen) levels as an indicator. However, the PSA test has the problem of producing a large number of false positives, and there is room for improvement in its predictive accuracy. Alternatively, needle biopsy is also used to collect prostate tissue and check for the presence or absence of cancer cells. While this test is used as a definitive diagnostic method, it is highly invasive and carries the risk of infection.
[0004] In recent years, various techniques have been reported for detecting prostate cancer using an animal's sense of smell (for example, Non-Patent Document 1).
[0005] Gordon, RT, et al. The use of canines in the detection of human cancer. J. Altern. Complement. Med. 14, 61-67 (2008).
[0006] An objective of the present disclosure is to provide a prostate cancer testing technique.
[0007] In view of the above problems, the present inventors have conducted extensive research and found that at least one selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone in a body fluid sample collected from a subject is a biomarker for prostate cancer. Based on this finding, the present inventors have conducted further research and have completed the invention of the present disclosure.
[0008] That is, the present disclosure encompasses the following aspects: Item 1. (1) A method for examining the possibility of prostate cancer, comprising a step of measuring the amount or concentration of at least one biomarker selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone in a body fluid sample collected from a subject.
[0009] Item 2. The method according to Item 1, further comprising: (2a) determining that the subject is highly likely to have prostate cancer if the amount or concentration of the biomarker detected in step (1) is equal to or greater than standard value A; and / or (2b) determining that the subject is low likely to have prostate cancer if the amount or concentration of the biomarker detected in step (1) is equal to or less than standard value B.
[0010] Item 3. The method according to Item 2, wherein the reference value A and the reference value B are values based on the maximum, average, percentile, or minimum value of the amount or concentration of the biomarker in a body fluid sample collected from a subject determined not to be affected by prostate cancer or a subject determined to be affected by prostate cancer.
[0011] Item 4. The method according to any one of Items 1 to 3, wherein the measurement method in step (1) is gas chromatography-mass spectrometry.
[0012] Item 5. The monitor ion in the gas chromatography mass spectrometry is: (A) at least one selected from the group consisting of an ion with m / z of 129, an ion with m / z of 59, and an ion with m / z of 100 when measuring dimethyl glutarate; (B) at least one selected from the group consisting of an ion with m / z of 121, an ion with m / z of 106, and an ion with m / z of 91 when measuring 2,6-xylidine; (C) at least one selected from the group consisting of an ion with m / z of 105, an ion with m / z of 59, and an ion with m / z of 77 when measuring 2-hydroxy-2-methylpropiophenone; (D) at least one selected from the group consisting of an ion with m / z of 163, an ion with m / z of 178, and an ion with m / z of 121 when measuring 2,6-di(propan-2-yl)phenol; (E) at least one selected from the group consisting of an ion with m / z of 163, an ion with m / z of 178, and an ion with m / z of 121 when measuring dimethyl glutarate; (F) when measuring succinate, at least one ion selected from the group consisting of an ion with an m / z of 115, an ion with an m / z of 55, an ion with an m / z of 59, and an ion with an m / z of 114; (G) when measuring 2-phenyl-2-propanol, at least one ion selected from the group consisting of an ion with an m / z of 43, an ion with an m / z of 121, and an ion with an m / z of 77; and (H) when measuring 3,5,5-trimetyl-2-cyclohexenone, at least one ion selected from the group consisting of an ion with an m / z of 138, an ion with an m / z of 82, and an ion with an m / z of 54.
[0013] Item 6. The method according to any one of Items 1 to 5, wherein the biomarkers are two or more types.
[0014] Item 7. The method according to any one of Items 1 to 6, wherein the body fluid sample is a urine sample.
[0015] Item 8. A biomarker for prostate cancer in a body fluid sample, comprising at least one member selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone.
[0016] Item 9. A prostate cancer diagnostic agent comprising at least one standard sample and / or detection agent selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone.
[0017] The present disclosure also encompasses the following aspect as another aspect: Item A. (1) A method for assisting in determining the possibility of prostate cancer, comprising a step of measuring the amount or concentration of at least one biomarker selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone in a body fluid sample collected from a subject.
[0018] Section B. (1) A method for measuring a prostate cancer biomarker, comprising a step of measuring the amount or concentration of at least one substance selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone in a body fluid sample collected from a subject.
[0019] Item C. At least one standard sample and / or detection agent selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone for use as a diagnostic agent for prostate cancer.
[0020] Item D. Use of at least one standard sample and / or detection agent selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone to test for prostate cancer.
[0021] Item E. Use of at least one standard sample and / or detection agent selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone for the manufacture of a prostate cancer test agent.
[0022] According to the present disclosure, a biomarker-based prostate cancer testing technique can be provided.
[0023] This figure shows a box plot representing the measurement results of dimethyl glutarate in Example 2. The vertical axis indicates urinary concentration, and on the horizontal axis, "preoperative" indicates the results of urine collected from prostate cancer patients before radical prostatectomy, and "postoperative" indicates the results of urine collected from prostate cancer patients after radical prostatectomy. The same subjects were used for both preoperative and postoperative data. In the box plot, the range indicated by the box represents the concentration distribution range of 25-75% of all samples, and the range indicated by the horizontal line represents the concentration distribution range of 10-90% of all samples. The horizontal bar in the box represents the median concentration for each group (preoperative and postoperative). The "+" in the box represents the mean. This figure shows the measurement results of 2-hydroxy-2-methylpropiophenone in Example 2. The vertical and horizontal axes, bars, and dotted lines are the same as in Figure 1. This figure shows the measurement results of 2,6-diisopropylphenol (2,6-di(propan-2-yl)phenol) in Example 2. The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 1. This figure shows the measurement results for dimethyl succinate in Example 2. The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 1. This figure shows the measurement results for acetophenone in Example 2. The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 1. This figure shows the measurement results for 2-phenyl-2-propanol in Example 2. The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 1. This figure shows the measurement results for 3,5,5-trimetyl-2-cyclohexenone in Example 2. The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 1. This figure shows a box plot representing the measurement results for dimethyl glutarate in Example 3. The vertical axis indicates urinary concentration, and on the horizontal axis, "healthy subjects" indicates the results for urine collected from healthy subjects, and "prostate cancer patients" indicates the results for urine collected from prostate cancer patients. In the box plots, the range indicated by the boxes represents the concentration distribution range of samples that accounted for 25-75% of all samples, and the range indicated by the horizontal lines represents the concentration distribution range of samples that accounted for 10-90% of all samples. The horizontal bars in the boxes represent the median concentrations in each group (pre-operative, post-operative). The "+" in the boxes represents the average value. The measurement results for 2-hydroxy-2-methylpropiophenone in Example 3 are shown.The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 8. This figure shows the measurement results for 2,6-diisopropylphenol (2,6-di(propan-2-yl)phenol) in Example 3. The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 8. This figure shows the measurement results for dimethyl succinate in Example 3. The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 8. This figure shows the measurement results for acetophenone in Example 3. The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 8. This figure shows the measurement results for 2-phenyl-2-propanol in Example 3. The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 8. This figure shows the measurement results for 3,5,5-trimetyl-2-cyclohexenone in Example 3. The vertical axis, horizontal axis, bars, and dotted line are the same as in Figure 8. This figure shows the measurement results for 2,6-xylidine in Example 3. The vertical axis, horizontal axis, bars, and dotted lines are the same as those in FIG.
[0024] In this specification, the expressions "contain" and "comprise" include the concepts of "contain," "comprise," "consist essentially of," and "consist only of."
[0025] In this specification, the expression "and / or" includes both "and" and "or." That is, the expression "A and / or B" includes both "A or B" and "A and B."
[0026] 1. Method for Testing for Possible Presence of Prostate Cancer The present disclosure relates to (1) a method for testing for possible prescribing of prostate cancer (sometimes referred to herein as the "testing method of the present disclosure"), comprising the step of measuring the amount or concentration of at least one biomarker selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone in a body fluid sample collected from a subject (sometimes referred to herein as the "target biomarker").
[0027] The present disclosure also relates to a biomarker for prostate cancer in a body fluid sample, the biomarker consisting of at least one selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone.
[0028] These will be explained below.
[0029] 1-1. Step (1) The prostate cancer to be tested is not particularly limited, and includes all types, degrees (for example, mild, moderate, severe), stages, and the like.
[0030] The subject is a living organism that is the target of the testing method of the present disclosure, and the species of the subject is not particularly limited. Examples of the subject include various mammals such as humans, monkeys, mice, rats, dogs, cats, and rabbits, and preferably humans.
[0031] The subject's prostate cancer status is not particularly limited. Examples of subjects include subjects whose prostate cancer status is unknown, subjects with no history of prostate cancer, subjects with a history of prostate cancer and who have been treated for prostate cancer, and subjects who have already been determined to have (or not have) prostate cancer by other testing methods (e.g., PSA testing). When the subject is a human, any individual can be tested, regardless of their medical history, including those considered healthy. For those considered healthy, the method is effective for early detection and early diagnosis of prostate cancer during general health checkups and comprehensive medical checkups. Furthermore, for subjects suspected of having prostate cancer, the testing method of the present disclosure can assist in prostate cancer diagnosis.
[0032] The body fluid sample is not particularly limited as long as it can contain the target biomarker. Examples of body fluid samples include body fluids such as blood that have passed through prostate cancer tissue, body fluids generated from such body fluids, and samples derived from these body fluids. Examples of body fluid-derived samples include samples obtained by purifying body fluids. The purification process is not particularly limited as long as it does not significantly reduce the amount or concentration of the target biomarker, and examples include treatments to remove salts, proteins, etc. (e.g., enzyme treatment, chromatography column purification, centrifugation, etc.). Specific examples of body fluid samples include urine, blood, cerebrospinal fluid, bodily secretions, saliva, and sputum; and samples derived from these body fluids. Among these, urine samples (urine and urine-derived samples) are preferred from the perspective of test efficiency. The method for collecting body fluids is not particularly limited, and for example, methods based on or similar to methods used in general periodic health checkups can be used. The timing of collection of body fluids is not particularly limited, and may be, for example, first thing in the morning, in the evening, before bed, or after or before meals. Body fluid samples can be used immediately after collection or preparation, or they can be frozen and stored before use. 2,6-di(propan-2-yl)phenol is reduced by oxidative denaturation at room temperature, with a half-life of 3-12 hours. Therefore, samples left at room temperature for more than half a day are unsuitable for use. The cryopreservation method is not particularly limited; for example, samples can be placed in a sealed glass container, frozen as quickly as possible (e.g., at approximately -80°C), and stored at a typical freezer temperature (e.g., approximately -20°C). The storage period is not particularly limited and can be one year or longer, but a shorter period is preferable. Body fluid samples may be used singly or in combination of two or more types.
[0033] The target biomarker is at least one selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone, the structural formulas of which are shown in Table 1.
[0034]
[0035] The target biomarkers to be measured in step (1) may be only one type, but may also be two or more, three or more, four or more, five or more, six or more, seven or more, or eight types. By combining more target biomarkers, prostate cancer testing and the like can be performed more accurately.
[0036] The method for measuring the amount or concentration of a target biomarker is not particularly limited as long as it is a method that can detect the target biomarker. From the viewpoint of detection sensitivity, the method is preferably mass spectrometry (MS method), more preferably gas chromatography mass spectrometry (GC / MS method).
[0037] The GC / MS method is carried out by separating a body fluid sample of a subject by gas chromatography and performing mass spectrometry on each separated fraction.
[0038] Gas chromatography can be performed according to or in accordance with known methods. Vaporization and introduction of a body fluid sample in gas chromatography can be performed by selecting an appropriate method from known methods depending on the state of the body fluid sample. For example, components of the body fluid sample can be adsorbed onto a volatile organic substance adsorbent material containing a general-purpose solid-phase microextraction fiber, followed by thermal desorption. The volatile organic substance adsorbent material is not particularly limited, but examples include silicone resins, with silicone elastomers being preferred. Examples of silicone resins and silicone elastomers include adsorbents made of polydimethylsiloxane (PDMS) or modified silicone compounds in which the methyl groups in the polymer chain of the silicone compound are substituted with vinyl or phenyl groups. The volatile organic substance adsorbent material may be used in combination with an appropriate carrier.
[0039] The carrier gas used in gas chromatography is not particularly limited as long as it is an inert gas. Examples of carrier gases include helium, nitrogen, argon, etc., with helium being preferred. The stationary phase used in gas chromatography is not particularly limited. Examples of stationary phases include polyethylene glycol, polymethylcyanoalkylsiloxane, polydimethylsiloxane / diphenylsiloxane, polydimethylsiloxane, etc. Among these, stationary phases with higher polarity are preferred. Specifically, polyethylene glycol, polymethylcyanoalkylsiloxane, polydimethylsiloxane / diphenylsiloxane, etc. are preferred, with polyethylene glycol and polymethylcyanoalkylsiloxane, etc., being more preferred, and polyethylene glycol being even more preferred. Other examples of stationary phases include silica gel, activated carbon, zeolite, activated alumina, etc. The detector used in gas chromatography is not particularly limited as long as it can detect a wide variety of components. Examples of detectors include thermal conductivity detectors (TCDs), flame ionization detectors (FIDs), electron capture detectors (ECDs), etc.
[0040] Mass spectrometry can be performed according to or in accordance with known methods. The ionization method in mass spectrometry is not particularly limited. Examples of ionization methods include electron ionization (EI), positive chemical ionization (PCI), and negative chemical ionization (NCI), with EI being preferred. The ionization voltage in EI is not particularly limited, but is typically about 70 V. The method for separating ionized sample molecules in mass spectrometry is not particularly limited. Examples of separation methods that can be used include time-of-flight, magnetic deflection, quadrupole, ion trap, Fourier transform ion cyclotron resonance, and tandem.
[0041] The amount or concentration of the target biomarker can be quantified by quantifying the amount of ions representing the target biomarker obtained by mass spectrometry. For example, the amount or concentration of the target biomarker can be calculated based on the amplitude value or area of the measured peak of the ion in the mass spectrum obtained by mass spectrometry. When using the amplitude value or area of the measured peak, a process to reduce background noise can also be added as necessary. Examples of monitor ions used for quantification include the following monitor ions: (A) When measuring dimethyl glutarate, at least one ion selected from the group consisting of an ion with m / z of 129, an ion with m / z of 59, and an ion with m / z of 100. (B) When measuring 2,6-xylidine, at least one ion selected from the group consisting of an ion with m / z of 121, an ion with m / z of 106, and an ion with m / z of 91. (C) When measuring 2-hydroxy-2-methylpropiophenone, at least one ion selected from the group consisting of an ion with m / z of 105, an ion with m / z of 59, and an ion with m / z of 77. (D) When measuring 2,6-di(propan-2-yl)phenol, at least one ion selected from the group consisting of an ion with m / z of 163, an ion with m / z of 178, and an ion with m / z of 121. (E) Dimethyl (F) When measuring succinat, at least one ion selected from the group consisting of ions with m / z of 115, ions with m / z of 55, ions with m / z of 59, and ions with m / z of 114. (G) When measuring 2-Phenyl-2-propanol, at least one ion selected from the group consisting of ions with m / z of 43, ions with m / z of 121, and ions with m / z of 77. (H) When measuring 3,5,5-Trimetyl-2-cyclohexenone, at least one ion selected from the group consisting of ions with m / z of 138, ions with m / z of 82, and ions with m / z of 54.
[0042] In a preferred embodiment of the present disclosure, among the monitor ions, the underlined ions can be used as quantitation ions, and the other ions can be used as reference ions.
[0043] In addition to the MS method, other methods for measuring the amount or concentration of a target biomarker can also be used, such as surface plasmon resonance and detection methods using metal oxide semiconductors, conductive polymers, polymer thin films, cholesteric liquid crystals, Schottky diodes, MOSFETs, thermistors, veristors, thermocouples, quartz oscillators, SAW devices, fluorescent substances, light-absorbing substances, olfactory cells, etc.
[0044] The testing method of the present disclosure, which includes step (1), can provide a measurement value for calculating a determination index for the possibility of developing prostate cancer, and preferably can further provide the determination index, thereby assisting in determining the possibility of developing prostate cancer.
[0045] Furthermore, the target biomarkers can be used in various aspects of prostate cancer testing, such as for screening for prostate cancer in health checkups, monitoring the effectiveness of prostate cancer treatment during or after treatment, detecting recurrence after prostate cancer treatment, and determining the prognosis of patients.
[0046] 1-2. Step (2) In one embodiment, the testing method of the present disclosure preferably further comprises: (2a) determining that the subject is highly likely to have prostate cancer if the amount or concentration of the biomarker detected in step (1) is equal to or greater than reference value A; and / or (2b) determining that the subject is low likely to have prostate cancer if the amount or concentration of the biomarker detected in step (1) is equal to or less than reference value B (these steps (2a) and (2b) may be collectively referred to as "step (2)"). Here, "the possibility of having prostate cancer" means "the possibility of having prostate cancer at the time of collection of the body fluid sample."
[0047] The testing method of the present disclosure, which includes step (2), makes it possible to determine the possibility of having prostate cancer. Furthermore, since the testing method of the present disclosure can determine the possibility of having prostate cancer with high accuracy, the testing method of the present disclosure, which includes step (2), can more reliably determine that a subject with prostate cancer "has prostate cancer (or does not have prostate cancer)" (i.e., it can further reduce the possibility of erroneously determining that a subject "does not have prostate cancer (or does have prostate cancer)").
[0048] The reference values (reference value A and reference value B, respectively) can be appropriately set by a person skilled in the art from the viewpoints of determination sensitivity, determination specificity, positive predictive value, negative predictive value, etc. The reference values may be either values set on an individual basis depending on race, age, etc., or preset values. The reference values may be values based on, for example, the maximum, average, percentile, or minimum value of the amount or concentration of the target biomarker in a body fluid sample collected from a subject determined not to be affected by prostate cancer or a subject determined to be affected by prostate cancer.
[0049] The "reference value" refers to a value that, when used as a reference to determine the presence or absence of disease, provides sufficiently high sensitivity (positive rate) and specificity (negative rate). For example, a value that shows a high positive rate in individuals with prostate cancer and a high negative rate in individuals without prostate cancer can be set as the reference value.
[0050] Here, "detection sensitivity" refers to the proportion of positive (abnormal) results (proportion of true positives) when a test is conducted on a group of people who have developed a specific disease. "Detection specificity" refers to the proportion of negative (normal) results (proportion of true negatives) when a test is conducted on a group of people who do not have a specific disease. "Positive predictive value" refers to the proportion of individuals who actually have the disease among subjects who test positive, and "negative predictive value" refers to the proportion of individuals who actually do not have the disease among subjects who test negative.
[0051] Methods for setting reference values are well known in the art. More specifically, reference values can be set, for example, by measuring the amount or concentration of a target biomarker in a biological sample collected from a subject determined not to be affected by prostate cancer or a subject determined to be affected by prostate cancer, and using the measured value to perform statistical analysis based on, for example, receiver operating characteristic (ROC) curve analysis (more specifically, a method using the Youden index is exemplified).
[0052] Such a reference value does not have a specific value, but varies depending on the subject population used when setting the reference value.
[0053] Even when the same subject is used, the measured values may differ depending on the analytical method used, so the reference values are set according to the analytical method used.
[0054] The reference value can also be set based on the measured value of a body fluid sample collected from the same subject a certain period of time before. The "certain period" is not particularly limited as long as it is a period within which the measured value may vary within the same subject. Examples include periods of about 1 month to 10 years, 2 months to 5 years, 3 months to 2 years, and 4 months to 1 year. Furthermore, if the subject has undergone treatment and / or surgery, the reference value can also be set based on the measured value of a body fluid sample collected before the treatment and / or surgery.
[0055] 2. Diagnosis of Prostate Cancer with Higher Accuracy When a subject is determined to have a high probability of having prostate cancer by the testing method of the present disclosure including step (2a), the presence of prostate cancer can be diagnosed with higher accuracy by combining the testing method of the present disclosure with a step (3) of applying a prostate cancer diagnostic method to the subject determined to have a high probability of having prostate cancer in step (2a). Furthermore, because the testing method of the present disclosure can determine the possibility of having prostate cancer with high accuracy, combining the testing method of the present disclosure with step (3) can more reliably diagnose subjects who truly have prostate cancer as having prostate cancer (i.e., it is possible to further reduce the possibility of subjects who do not have prostate cancer being diagnosed in step (3), the possibility of misdiagnosing them as not having prostate cancer, and the possibility of excluding subjects who have prostate cancer from the diagnosis target of step (3)).
[0056] The method for diagnosing prostate cancer to be used in step (3) is not particularly limited, and various known diagnostic methods can be used. Examples of such diagnostic methods include intrarectal palpation, ultrasound, MRI, CT, and needle biopsy. The diagnostic methods may be used alone or in combination of two or more.
[0057] 3. Treatment of Prostate Cancer If a subject is determined to have a high probability of having prostate cancer by the testing method of the present disclosure including step (2a), or if a subject is diagnosed with prostate cancer by step (3), a further step (4) (step (4)) of administering prostate cancer treatment to the subject determined to have a high probability of having prostate cancer in step (2a) or diagnosed with prostate cancer in step (3) can be carried out, thereby treating the subject's prostate cancer. Furthermore, since the testing method of the present disclosure can determine the possibility of having prostate cancer with high sensitivity, by further combining step (4) with the testing method of the present disclosure or a combination of the testing method of the present disclosure and step (3), subjects who truly have prostate cancer can be more reliably treated (i.e., the possibility of excluding subjects who truly have prostate cancer from treatment can be further reduced).
[0058] The method for treating prostate cancer is not particularly limited, and various known treatment methods can be used. Examples of treatment methods include chemotherapy, surgical treatment, radiation therapy, and immunotherapy. These can be performed according to known methods.
[0059] The therapeutic agent used in chemotherapy is not particularly limited, and various anticancer agents can be used. Examples of anticancer agents include alkylating agents, antimetabolites, microtubule inhibitors, antibiotic anticancer agents, topoisomerase inhibitors, platinum compounds, molecular targeted drugs, hormones, and biological agents. Examples of alkylating agents include cyclophosphamide, ifosfamide, nitrosoureas, dacarbazine, temozolomide, nimustine, busulfan, melphalan, procarbazine, and ranimustine. Examples of antimetabolites include enocitabine, carmofur, capecitabine, tegafur, tegafur-uracil, tegafur-gimeracil-oteracil potassium, gemcitabine, cytarabine, cytarabine ocfosfate, nelarabine, fluorouracil, fludarabine, pemetrexed, pentostatin, methotrexate, cladribine, doxifluridine, hydroxycarbamide, mercaptopurine, etc. Examples of microtubule inhibitors include alkaloid anticancer drugs such as vincristine, and taxane anticancer drugs such as docetaxel and paclitaxel. Antibiotic anticancer drugs include, for example, mitomycin C, doxorubicin, epirubicin, daunorubicin, bleomycin, actinomycin D, aclarubicin, idarubicin, pirarubicin, peplomycin, mitoxantrone, amrubicin, zinostatin stimalamer, etc. Topoisomerase inhibitors include CPT-11, irinotecan, nogitecan, which have topoisomerase I inhibitory activity, and etoposide and sobuzoxane, which have topoisomerase II inhibitory activity. Platinum drugs include, for example, cisplatin, nedaplatin, oxaliplatin, carboplatin, etc. Examples of hormone agents include dexamethasone, finasteride, tamoxifen, astrozole, exemestane, ethinylestradiol, chlormadinone, goserelin, bicalutamide, flutamide, prednisolone, leuprorelin, letrozole, estramustine, toremifene, fosfestrol, mitotane, methyltestosterone, medroxyprogesterone, and mepitiostane.Examples of biologics include interferon α, β, and γ, interleukin 2, ubenimex, and dried BCG. Examples of molecular targeted drugs include nivolumab, pembrolizumab, rituximab, alemtuzumab, trastuzumab, cetuximab, panitumumab, imatinib, dasatinib, nilotinib, gefitinib, erlotinib, temsirolimus, bevacizumab, VEGF trap, sunitinib, sorafenib, tosituzumab, bortezomib, gemtuzumab ozogamicin, ibritumomab ozogamicin, ibritumomab tiuxetan, tamibarotene, and tretinoin. In addition to the molecular targeted drugs specified herein, other molecular targeted drugs include inhibitors that target angiogenesis, such as human epidermal growth factor receptor 2 inhibitors, epidermal growth factor receptor inhibitors, Bcr-Abl tyrosine kinase inhibitors, epidermal growth factor tyrosine kinase inhibitors, mTOR inhibitors, and vascular endothelial growth factor receptor 2 inhibitors (α-VEGFR-2 antibodies), various tyrosine kinase inhibitors such as MAP kinase inhibitors, inhibitors that target cytokines, proteasome inhibitors, and antibody-anticancer drug combinations. These inhibitors also include antibodies. The therapeutic agent may be a single type, or a combination of two or more types.
[0060] 4. Prostate Cancer Test Agent In one aspect, the present disclosure relates to a prostate cancer test agent (sometimes referred to herein as the "test agent of the present disclosure") comprising at least one standard sample and / or detection agent selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone. This is described below.
[0061] The standard sample is at least one compound selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone, or a modified version thereof, but is not particularly limited thereto. The standard sample can be used, for example, to prepare a calibration curve when quantifying a target biomarker. The standard sample is either a known compound or can be obtained from a known compound using an existing compound modification method.
[0062] The detection agent is not particularly limited as long as it can be used to detect the target biomarker. When the target biomarker has a structure (atomic group, etc.) that develops color when converted into another compound by a chemical reaction, a substance that causes that chemical reaction (coloring reagent) can be used as the detection agent. Examples of coloring reagents include phosphomolybdic acid, anisaldehyde, cerium ammonium molybdate, sulfuric acid, ninhydrin, Dragendorff, dinitrophenylhydrazine, palladium chloride, basic potassium permanganate, bromocresol green, iron (II) chloride, and the like. Furthermore, antibodies against compounds that constitute the target biomarker, detection tags that assist in the detection of the target biomarker by mass spectrometry, and the like can also be used as detection agents.
[0063] The test agent of the present disclosure may be in the form of a composition containing a standard sample and / or a detection agent. The composition may contain other components as needed. Examples of other components include bases, carriers, solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrants, lubricants, thickeners, moisturizers, colorants, fragrances, chelating agents, etc.
[0064] The test agent of the present disclosure may be used in a kit containing a standard sample and / or a detection agent. The kit may also contain instruments, reagents, etc. that can be used to carry out the test method of the present disclosure.
[0065] The present invention will be described in detail below based on examples, but the present invention is not limited to these examples.
[0066] Reference Example 1. Preparation of Urine Samples The urine samples of the subjects (6 healthy subjects and 14 prostate cancer patients (hereinafter sometimes simply referred to as "patients")) used in the following Examples 1 and 2 were 5 days' worth of urine provided by men who had given informed consent. The age, prostate cancer stage, and treatment history of each subject are shown in Table 2.
[0067]
[0068] The majority of patients have stage II prostate cancer (cancer confined to the prostate), which is classified as the earliest stage of prostate cancer.
[0069] Patients underwent radical prostatectomy and were determined to be negative for prostate cancer by PSA testing three months after surgery. Postoperative urine samples were collected from these patients.
[0070] All urine samples were filtered through a 0.2 μm pore size filter immediately after collection to remove impurities and sterilize them, and then stored at −80° C. until use in the measurement.
[0071] Example 1. Identification of prostate cancer markers using solid-phase microextraction-gas chromatography-mass spectrometry To reduce personal odors due to diet and genetic predisposition, as well as odors caused by occult blood, equal volumes of urine samples from five patients (aged 62-77, cancer stage II, Gleason score 7.2 (average)) collected over five days were mixed together to prepare a mixed urine sample. Similarly, six healthy individuals (aged 52-75) were divided into two groups of three individuals, and equal volumes of urine samples from three individuals collected over six days were mixed together to prepare a mixed urine sample.
[0072] When measuring urine from patients after endocrine therapy, urine samples from five patients (58-80 years old, four stage II, one stage III, Gleason score 6.0 (average)) who had undergone radical prostatectomy after endocrine therapy were mixed over five days in the same manner as above.
[0073] Mixed urine samples were placed in a sealed glass container and heated to capture a large amount of volatile components, which were then analyzed by mass spectrometry. To concentrate dilute components, compounds were adsorbed onto a solid-phase microextraction fiber coated with divinylbenzene / carboxen / polydimethylsiloxane (DVB / CAR / PDMS) (Supelco, #57348-U, Sigma-Aldrich).
[0074] 250 μL of urine was placed in a 2 mL glass vial and incubated at 40°C for 30 minutes. The fiber was then inserted and held for 20 minutes to adsorb the compounds. The compound-adsorbed fiber was inserted into the injection port of a GC-MS (GCMS-TQ8030, Shimadzu), the compounds were desorbed, and the volatile components were measured. Measurements were performed twice for each sample. As a quality control sample during analysis, an equal volume of urine was taken from all urine samples to be analyzed, regardless of whether they were from healthy individuals or patients, and this was then analyzed together. The GC-MS analysis conditions were as follows:
[0075] <Analysis conditions> ・Analytical equipment: GCMS-TQ8030 system (Shimadzu Corporation) ・Column: CP Sil 8CB (30 m × 0.25 mm Internal Diameter × 0.25 μm film thickness, Agilent Technologies) ・Mobile phase gas: Helium, 1.0 mL / min, constant flow rate ・Temperature increase conditions: 40°C (0 min) → 40°C (5 min) → 240°C (45 min) → 240°C (50 min) ・Injection conditions: 2 minutes, 240°C, splitless ・Scan range: m / z 40-500, 0.2 scans / sec ・Ion current temperature: 180°C ・Interface temperature: 300°C ・Ionization voltage: 70 eV.
[0076] Based on all peak height values obtained from the analysis of the QC samples, the relative standard deviation (%RSD) for each peak was calculated for each analysis. Peaks with a %RSD of <30% and peaks greater than or equal to 5 times the negative control were selected for analysis. Peaks prone to detection variability due to technical factors during the instrumental analysis process and noise peaks were excluded, resulting in 160 peaks that were reproducibly detected for each analysis. Next, the pre- and post-operative mixed fluids of the healthy volunteers and prostate cancer patients were measured by GC-MS. Principal component analysis was performed using the peak height values as variables, resulting in a new composite variable consisting of the first and second principal components. The principal component scores for each mixed urine were plotted with the first and second principal components as axes.
[0077] Samples from healthy individuals and prostate cancer patients (preoperative) plotted at different positions along the PC1 axis, indicating clearly different volatile profiles. Comparing healthy individuals and prostate cancer and endocrine-treated patients (preoperative) also plotted at different positions, indicating clearly different volatile profiles. However, the difference was not as great as that between healthy individuals and prostate cancer patients (preoperative), and the prostate cancer and endocrine-treated patients (preoperative) samples were closer to the healthy individuals along the PC1 axis. The first principal component showed a large positive correlation for healthy individuals and a large negative correlation for prostate cancer patients, suggesting that the first principal component represents the axis representing health status. Based on this, the results showing that the prostate cancer and endocrine-treated patients (preoperative) samples were closer to the healthy individuals may be due to the suppressive effect of endocrine treatment on cancer progression, reducing the cancer-specific volatile compounds released from cancer tissue, resulting in a profile closer to that of healthy individuals.
[0078] The samples from prostate cancer patients (postoperative) and those from prostate cancer patients with endocrine therapy (postoperative) were plotted closer to the positive PC1 axis than the samples from preoperative cancer patients. The presence or absence of cancer is thought to alter the profile of volatile compounds released into urine.
[0079] Similarly, the principal component scores of individual peaks obtained by GC-MS analysis were plotted on a PC1-PC2 graph. Based on the above results, peaks with large negative first principal component scores were considered to represent a group of components characteristic of prostate cancer. Eight compounds in this group (dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone) were identified as prostate cancer markers.
[0080] Example 2. Quantitative analysis of volatile organic compounds in human urine (changes in urinary concentrations before and after surgery) Using preoperative and postoperative urine samples from five cancer patients, the concentrations of the seven target compounds identified in Example 1 (dimethyl glutarate, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone) were quantitatively analyzed. Each urine sample was obtained by mixing equal volumes of five urine samples. Details of the quantitative analysis method are as follows.
[0081] <Preparation of Test Solutions> (1) Standard Stock Solution: The target compound was diluted with DMSO to 10, 20, 50, 200, 500, 2000, 5000, 10,000, and 20,000 ng / mL (equivalent concentrations in the sample: 1, 2, 5, 20, 50, 200, 500, 1000, and 2000 ng / mL). These were used as standard stock solutions. (2) Standard Solutions: 250 μL of purified water was added to a 20 mL headspace vial, followed by 25 μL of each calibration curve standard stock solution. (3) Sample Solutions and Blank Solutions: 250 μL of the sample was added to a 20 mL headspace vial, followed by 25 μL of DMSO. A blank solution was prepared using the same procedure but with TOC-purified water instead of the sample. (4) Added sample solution: 250 μL of the sample was added to a 20 mL headspace vial, and 25 μL of standard stock solution at 200, 500, and 2000 ng / mL was added.
[0082] <Apparatus> GC-MS: GCMS-QP2010Ultra (Shimadzu Corporation) Autosampler: AOC-5000Plus (Shimadzu Corporation) (SPME section) SPME fiber: Two layers of divinylbenzene dispersion, Carboxen dispersion, and polydimethylsiloxane (DVB / CAR / PDMS) Equilibration temperature in vial: 40°C Equilibration time in vial: 30 min Extraction time: 20 min Desorption time: 4 min Fiber heating cleaning temperature: 260°C Fiber heating cleaning time: 10 min (GC section) Column: InertCap Pure WAX inner diameter 0.25 mm, length 30 m, film thickness 0.5 μm (GL Sciences Inc.) Column temperature: 40°C (5 min hold) → 5°C / min → 240°C (5 min hold) Injection port temperature: 240°C Carrier gas control mode: Carrier gas flow rate 1 The linear velocity was controlled to mL / min. Sample introduction method: splitless. Injection volume: 1 μL (MS section). Ionization method: EI. Interface temperature: 240°C. Ion source temperature: 200°C. Gain: relative value from autotuning result +0.2 kV. Mode: scan. Scan speed: 0.2 scan / sec.
[0083] Each standard solution was measured using InertCap Pure WAX. After obtaining a total ion chromatogram (TIC), the peaks of the target compounds were identified from the mass spectrum of the detected peaks, and monitor ions were selected (Table 3).
[0084]
[0085] The results are shown in Figures 1 to 7. The seven target compounds were components that showed higher levels in the pre-operative samples than in the post-operative samples. This indicated that these compounds were derived from prostate cancer tissue.
[0086] Example 3 Quantitative Analysis of Volatile Organic Compounds in Human Urine (Comparison of Urinary Concentrations between Healthy Subjects and Patients) Using four days' worth of urine from six healthy subjects (24 samples in total) and two to five days' worth of urine from four prostate cancer patients (13 samples in total), the concentrations of the eight target compounds identified in Example 1 (Dymethyl glutarate, 2-Hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, Dimethyl succinate, Acetophenone, 2-Phenyl-2-propanol, 3,5,5-Trimetyl-2-cyclohexenone, and 2,6-Xylidine) were quantitatively analyzed. The quantitative analysis method was the same as in Example 2.
[0087] The monitor ions of 2,6-Xylidine not selected in Example 2 are as follows:
[0088]
[0089] The results are shown in Figures 8 to 15. The eight target compounds were found to be components that showed higher levels in samples from prostate cancer patients than in samples from healthy individuals. This indicated that these compounds were derived from prostate cancer tissue.
Claims
1. (1) A method for testing for the possibility of having prostate cancer, comprising a step of measuring the amount or concentration of at least one biomarker selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone in a body fluid sample collected from a subject.
2. moreover, (2a) determining that the subject is highly likely to be affected with prostate cancer if the amount or concentration of the biomarker detected in the step (1) is equal to or higher than standard value A, and / or (2b) determining that the subject is low likely to be affected with prostate cancer if the amount or concentration of the biomarker detected in the step (1) is equal to or lower than standard value B. The method of claim 1 , comprising:
3. The method according to claim 2, wherein the reference value A and the reference value B are values based on the maximum, average, percentile, or minimum value of the amount or concentration of the biomarker in a body fluid sample collected from a subject determined not to be affected by prostate cancer or a subject determined to be affected by prostate cancer.
4. The method according to claim 1, wherein the measurement method in step (1) is gas chromatography-mass spectrometry.
5. The monitor ion in the gas chromatography mass spectrometry is (A) When measuring dimethyl glutarate, the ion is at least one selected from the group consisting of an ion having an m / z of 129, an ion having an m / z of 59, and an ion having an m / z of 100; (B) When measuring 2,6-Xylidine, the ion is at least one selected from the group consisting of an ion having an m / z of 121, an ion having an m / z of 106, and an ion having an m / z of 91; (C) when measuring 2-hydroxy-2-methylpropiophenone, at least one ion selected from the group consisting of an ion with m / z of 105, an ion with m / z of 59, and an ion with m / z of 77; (D) When measuring 2,6-di(propan-2-yl)phenol, the ion is at least one selected from the group consisting of an ion having an m / z of 163, an ion having an m / z of 178, and an ion having an m / z of 121; (E) When dimethyl succinate is measured, the ion is at least one selected from the group consisting of an ion having an m / z of 115, an ion having an m / z of 55, an ion having an m / z of 59, and an ion having an m / z of 114; (F) When acetophenone is measured, the ion is at least one selected from the group consisting of an ion having an m / z of 105, an ion having an m / z of 77, and an ion having an m / z of 120; (G) When measuring 2-Phenyl-2-propanol, the ion is at least one selected from the group consisting of an ion having an m / z of 43, an ion having an m / z of 121, and an ion having an m / z of 77; (H) When 3,5,5-Trimetyl-2-cyclohexenone is measured, the ion is at least one selected from the group consisting of an ion having an m / z of 138, an ion having an m / z of 82, and an ion having an m / z of 54.
6. The method according to any one of claims 1 to 5, wherein the biomarkers are two or more.
7. The method according to any one of claims 1 to 5, wherein the body fluid sample is a urine sample.
8. A biomarker for prostate cancer comprising at least one member selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone in a body fluid sample.
9. A prostate cancer testing agent comprising at least one standard sample and / or detection agent selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone.
10. (1) A method for measuring a prostate cancer biomarker, comprising a step of measuring the amount or concentration of at least one substance selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone in a body fluid sample collected from a subject.
11. At least one standard sample and / or detection agent selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone, for use as a diagnostic agent for prostate cancer.
12. Use of at least one standard sample and / or detection agent selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone for testing prostate cancer.
13. Use of at least one standard sample and / or detection agent selected from the group consisting of dimethyl glutarate, 2,6-xylidine, 2-hydroxy-2-methylpropiophenone, 2,6-di(propan-2-yl)phenol, dimethyl succinate, acetophenone, 2-phenyl-2-propanol, and 3,5,5-trimetyl-2-cyclohexenone for the manufacture of a prostate cancer test agent.
